BioLine RX Ltd Total Assets
BioLine RX Ltd total assets. Based on the latest financial reports, BioLine RX Ltd (BLRX) holds total assets worth ILA33.26 Million ILA (≈ $89.16K USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is BioLine RX Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of BioLine RX Ltd (2005–2025)
Total assets of BioLine RX Ltd from 2005 to 2025. This chart illustrates how BioLine RX Ltd's total assets have evolved over time, based on quarterly financial data. See latest BioLine RX Ltd stock price today for real-time trading data and today's change.
BioLine RX Ltd - Asset Composition Analysis
BioLine RX Ltd Total Assets Breakdown (December 2025)
BioLine RX Ltd total assets breakdown as of December 2025. BioLine RX Ltd's total assets of ILA33.26 Million consist of 57.9% current assets and 42.1% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 8.0% |
| Accounts Receivable | ILA456.09K | 1.1% |
| Inventory | ILA2.15 Million | 5.3% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA16.37 Million | 40.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how BioLine RX Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BioLine RX Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioLine RX Ltd's current assets represent 57.9% of total assets in 2025, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 8.0% of total assets in 2025, down from 30.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 40.0% of total assets.
BioLine RX Ltd Competitors by Total Assets
Key competitors of BioLine RX Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
BioLine RX Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 2.06 | 6.09 |
| Quick Ratio | 1.04 | 1.87 | 6.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA2.65 Million | ILA16.38 Million | ILA52.53 Million |
BioLine RX Ltd - Advanced Valuation Insights
This section examines the relationship between BioLine RX Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | ILA40.91 Million |
| Market Capitalization | $8.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioLine RX Ltd's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: BioLine RX Ltd's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BioLine RX Ltd (2005–2025)
The table below shows the annual total assets of BioLine RX Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ILA40.91 Million ≈ $109.69K |
+5.16% |
| 2024-12-31 | ILA38.91 Million ≈ $104.31K |
-39.14% |
| 2023-12-31 | ILA63.92 Million ≈ $171.38K |
-16.31% |
| 2022-12-31 | ILA76.38 Million ≈ $204.78K |
-6.15% |
| 2021-12-31 | ILA81.39 Million ≈ $218.21K |
+72.11% |
| 2020-12-31 | ILA47.29 Million ≈ $126.78K |
-11.72% |
| 2019-12-31 | ILA53.57 Million ≈ $143.61K |
-4.74% |
| 2018-12-31 | ILA56.23 Million ≈ $150.76K |
-7.76% |
| 2017-12-31 | ILA60.97 Million ≈ $163.45K |
+56.57% |
| 2016-12-31 | ILA38.94 Million ≈ $104.39K |
-24.10% |
| 2015-12-31 | ILA51.30 Million ≈ $137.54K |
+41.85% |
| 2014-12-31 | ILA36.17 Million ≈ $96.96K |
+81.30% |
| 2013-12-31 | ILA19.95 Million ≈ $53.48K |
-17.93% |
| 2012-12-31 | ILA24.31 Million ≈ $65.17K |
-17.15% |
| 2011-12-31 | ILA29.34 Million ≈ $78.65K |
-81.02% |
| 2010-12-31 | ILA154.61 Million ≈ $414.51K |
-2.86% |
| 2009-12-31 | ILA159.17 Million ≈ $426.72K |
+37.54% |
| 2008-12-31 | ILA115.73 Million ≈ $310.26K |
-44.33% |
| 2007-12-31 | ILA207.88 Million ≈ $557.33K |
+933.06% |
| 2006-12-31 | ILA20.12 Million ≈ $53.95K |
-2.27% |
| 2005-12-31 | ILA20.59 Million ≈ $55.20K |
-- |
About BioLine RX Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more